Chinese orthopedic 3D printing leader Aikang Medical acquired libeier, an orthopedic implant and surgical instrument company owned by Medtronic, and became a leader in the field of orthopedics in China.
On April 6, 2020, BJAK Medical Holdings Co., Ltd. and Medtronic China Kanghui Holdings signed an equity sale agreement for US $ 40,200,000 (approximately RMB 280 million, subject to adjustment) to acquire the entire equity of Medtronic Beijing Libeier Bioengineering Research Institute Co., Ltd. After the acquisition is completed, libeier will become a wholly-owned subsidiary of Aikang Medical. Since then, AK Medical has three major orthopedic consumable product lines for joints, spine and trauma.
BJAK Medical
China's leader in bone and joint industry
BJAK Medical is currently the leader in China's bone and joint industry, occupying a leading position in the market share of knee and hip joints. BJAK Medical is a pioneer in the R & D, manufacturing and commercial application of 3D printed metal implants in China. It is also the largest orthopedic 3D printed metal implant manufacturer in the Asia-Pacific region, with a standardized metal 3D printed orthopedic implant registration certificate Three, achieved the innovative R & D of 3D printed standardized metal implants and the creation of clinical commercial applications.
In the development and clinical application of 3D printed custom spine and joint orthopedic implants, BJAK Medical has developed a variety of innovative 3D printed custom metal implant prostheses to complete clinical applications and achieve significant clinical results. 9 records have been completed on 3D printed custom metal implant prostheses such as spine and joints, which can provide a more complete and safer solution for more clinically difficult and serious diseases.
Becoming a leader in the field of orthopedics in China is the long-term strategic goal of BJAK Medical. In 2018, through the acquisition of the British JRI company, BJAK Medical took an important step in the development of artificial joint surface technology and overseas markets; this acquisition of Medtronic's libeier is a major move in the company's layout in the spine and trauma field.
Joint spine trauma
Comprehensively improve the BJAK medical product line
libeier was established in 1996 in Beijing, China. It is a company engaged in the production, sale and research of orthopedic implants and surgical instruments. As a wholly-owned subsidiary of Medtronic, it has a mature spinal and trauma product line, stable and high-quality product quality, and a marketing network covering more than 500 hospitals. It is a well-known spinal trauma brand in China.
After BJAK Medical completes the acquisition of libeier, the company's 3D printed spinal fusion system will combine libeier's mature spinal internal fixation system to launch a more complete product portfolio in spinal products and clinical solutions.
In addition to the spine field, libeier has also been cultivating in the trauma field for many years, with bone plate, intramedullary nails and fixation systems and other trauma products. After the acquisition, BJAK Medical can combine the company's 3D ITI preoperative planning, 3D guide technology and 3D bone filling system with Lebel's rich trauma product line, apply it to the field of trauma, and drive the innovative development of trauma clinical applications. The rich medical device license combination will further promote the development of trauma products, bring innovative solutions to trauma treatment, and further enhance the Group's competitiveness.
The acquisition of Medtronic's companies is a solid step towards the realization of BJAK Medical Group's strategy
libeier has Medtronic's stable and complete production and quality control system. With this acquisition, BJAK Medical can fully utilize Medtronic's first-class quality control system to enrich the supply of spinal products with large-scale quality while enriching its product line; through this acquisition, BJAK Medical's existing sales network and libeier's sales network can penetrate and complement each other, obtaining significant business channel expansion opportunities.
At present, BJAK Medical has R & D and manufacturing bases in Beijing, Changzhou, China and Sheffield, UK, with 51 registration certificates. The products have obtained FDA and CE certification, and are sold in more than 30 countries and regions in the world, covering more than 6,000 hospitals. . This acquisition is conducive to further enriching the company's product portfolio, expanding the company's R & D and innovation capabilities, and improving marketing and service levels, which is a solid step in achieving BJAK Medical Group's strategy.